Jun 03, 2019 7:54am EDT NeuroRX to Present Phase 2 Efficacy Data for NRX-101 at 2019 BIO International Convention
May 30, 2019 8:33am EDT NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression
Dec 13, 2018 7:02am EST NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression
Nov 13, 2018 8:02am EST NeuroRx Receives FDA Breakthrough Therapy Designation for NRX-101, First Oral Drug Targeting Suicidal Bipolar Depression
Sep 05, 2018 8:00am EDT NeuroRx to Present at the Annual Rodman & Renshaw Global Investment Conference on Sept 5, 2018
Sep 04, 2018 9:10am EDT NeuroRx Announces Phase 2 Data from NRX-101, Initiates Pivotal Study for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB)
Jun 11, 2018 8:49am EDT NeuroRx, Inc. Completes Phase 2b/3 Feasibility Enrollment for First Glx-Targeted Oral Drug Targeting Suicidal Bipolar Depression
May 07, 2018 7:00am EDT NeuroRx Receives Special Protocol Agreement (SPA) and Biomarker Letter of Support from FDA for Pivotal Studies of NRX-101 to treat Severe Bipolar Depression in Patients with Acute Suicidal Ideation & Behavior
Dec 27, 2017 8:30am EST NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)
